Innovative immunotherapy research has pinpointed new molecular regulators that could reshape cancer treatment. T regulatory cells expressing a shortened FOXP3 isoform bolster cytotoxic T cell antitumor immunity, potentially overcoming immunosuppression in tumors. Additionally, the transcription factor SOX2 has been linked to cisplatin resistance, suggesting therapeutic avenues to sensitize resistant cancers.